Company and Novo Nordisk A/S ("Novo Nordisk") which restated the
rights and responsibilities of the parties. Novo Nordisk retains
exclusive, worldwide rights to the E1-I.N.T.(TM) program and the
Company regains exclusive ownership and rights to all other I.N.T.
(TM) programs, including GLP1-I.N.T.(TM);
- The Company and the Juvenile Diabetes Research Foundation
International ("JDRF"), located in the United States, entered into an
agreement in which the JDRF will provide milestone driven funding of
up to US$4 million to assist in the expedited development of GLP1-
I.N.T.(TM) over a two year period.
- On August 20, 2007 the Company's common shares began trading on the
NASDAQ Capital Market under the symbol "TTHI". The Company's common
shares will continue to trade on the Toronto Stock Exchange in
addition to the NASDAQ;
- On July 9, 2007 the Company completed a consolidation of its issued
and outstanding common shares on the basis of one (1) post-
consolidation common share for every nine (9) pre-consolidation
common shares. The share consolidation was effected to satisfy the
NASDAQ's listing criteria regarding minimum bid price.
- On July 11, 2007 the Company completed a private placement financing
issuing 1,736,107 common shares at a price of $14.40 per common
share, raising gross proceeds of approximately $25,000,000 from a
number of funds managed by Oracle Investment Management Inc., The
Invus Group LLC, and a large Boston based investment management
company. The Company has incurred total share issuance costs to date
of $1,023,596, resulting in net cash proceeds of $23,976,404;
- On November 8, 2006 the Company comple
|SOURCE Transition Therapeutics Inc.|
Copyright©2007 PR Newswire.
All rights reserved